CNBX 주가 차트
CNBX 수입
CNBX Pharmaceuticals Inc
$0
33.33%
$0
종가: May 20, 16:00:00 GMT-4
$0
0%
$0
애프터마켓: May 20, 17:57:50 GMT-4
뒤로
CNBX Pharmaceuticals Inc (CNBX) 수입
Earnings FAQ
CNBX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
CNBX Pharmaceuticals Inc CNBX의 지난 분기 매출 실적은 어땠나요?
CNBX Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
CNBX Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
CNBX Pharmaceuticals Inc는 언제 수익을 보고하나요?
CNBX Pharmaceuticals Inc의 예상 수익은 얼마인가요?
CNBX Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.0001
시가
$0.0001
일일 범위
$0.0001 - $0.0003
52주 범위
$0.0001 - $0.0063
거래량
2.6M
평균 거래량
33.8M
배당수익률
--
EPS(TTM)
-0.00
시가총액
$174.1K
CNBX란 무엇인가요?
CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. The company is headquartered in Bethesda, Maryland and currently employs 1 full-time employees. The company went IPO on 2007-07-02. The Company’s first lead product candidate is Cannabics SR, the oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The firm intends to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
